Currently, there are 209.50M common shares owned by the public and among those 142.63M shares have been available to trade.
The company’s stock has a 5-day price change of -11.11% and -27.55% over the past three months. ALLO shares are trading -9.86% year to date (YTD), with the 12-month market performance down to -40.19% lower. It has a 12-month low price of $1.78 and touched a high of $5.78 over the same period. ALLO has an average intraday trading volume of 2.56 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.27%, -17.27%, and -28.34% respectively.
Institutional ownership of Allogene Therapeutics Inc (NASDAQ: ALLO) shares accounts for 68.30% of the company’s 209.50M shares outstanding.
It has a market capitalization of $402.57M and a beta (3y monthly) value of 0.85. The earnings-per-share (ttm) stands at -$1.56. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.24% over the week and 8.59% over the month.
Analysts forecast that Allogene Therapeutics Inc (ALLO) will achieve an EPS of -0.33 for the current quarter, -0.35 for the next quarter and -1.39 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.41 while analysts give the company a high EPS estimate of -0.41. Comparatively, EPS for the current quarter was -0.51 a year ago. Earnings per share for the fiscal year are expected to increase by 36.25%, and -1.64% over the next financial year.
Looking at the support for the ALLO, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on August 08, 2024, with the firm’s price target at $13-$11. Piper Sandler coverage for the Allogene Therapeutics Inc (ALLO) stock in a research note released on May 31, 2024 offered a Overweight rating with a price target of $11. Citigroup on their part issued Buy rating on December 08, 2023.
